INCRAFT覆膜支架治疗腹主动脉瘤的三年安全性与有效性:INSIGHT研究结果
INSIGHT研究是一项多中心、前瞻性、开放标签、上市后研究,纳入2015至2016年间23个欧洲中心150例接受INCRAFT系统治疗肾下腹主动脉瘤的受试者,评估EVAR的中期耐久性。3年主要临床成功率为84.0%(126/150),无动脉瘤相关死亡、支架迁移或动脉瘤相关破裂,3年免于二次干预率为80%,免于动脉瘤囊扩张率为96.5%。
要点
- 3年主要临床成功率为84.0%(126/150),无动脉瘤相关死亡、支架迁移或动脉瘤相关破裂。
- 3年免于全因死亡率为89.4%,免于二次干预率为80%,免于动脉瘤囊扩张率为96.5%。
- 3年免于IA型和IB型内漏分别为93.3%和98.6%,2例(1.3%)检出支架断裂但无临床后遗症。
核心结论
- 在多中心真实世界研究环境中,使用低Profile的INCRAFT装置治疗腹主动脉瘤与持续的临床成功和3年内较低的再干预率相关。
研究设计与样本
- 多中心、前瞻性、开放标签、上市后研究,2015至2016年间纳入23个欧洲中心150例接受INCRAFT系统治疗肾下腹主动脉瘤的受试者。
- 临床和影像学数据前瞻性收集,按方案规定的监测随访门诊在植入后1、6、12个月及之后每年进行。
- 采用Kaplan-Meier估计评估晚期结局,独立临床事件委员会审查所有事件,1年内CT扫描由独立核心实验室审查。
主要发现
- 3年主要临床成功率为84.0%(126/150)。
- 3年内无动脉瘤相关死亡、支架迁移或动脉瘤相关破裂;2例(1.3%)检出支架断裂,无临床后遗症。
- 3年免于全因死亡率为89.4%,免于二次干预率为80%,免于动脉瘤囊扩张率为96.5%。
- 3年免于IA型内漏为93.3%,免于IB型内漏为98.6%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Preliminary results of the INSIGHT study showed that the low-profile INCRAFT Abdominal Aortic Aneurysm (AAA) Stent-Graft System was safe and effective in the endovascular aneurysm repair (EVAR). This study aimed to assess the durability and the midterm effectiveness of EVAR using the INCRAFT System in the framework of a multicenter, prospective, open-label, post-approval study. MATERIALS AND METHODS: Between 2015 and 2016, 150 subjects from 23 European centers treated with the INCRAFT System for an infrarenal AAA were included. Clinical and radiologic data were prospectively collected and analyzed using protocol-specified, monitored follow-up clinic visits at 1, 6, and 12 months post-implantation and annually after that. The clinical success at 3 years was determined. Freedom from overall and aneurysm-related mortality, type I endoleak, secondary interventions, and aneurysm sac enlargement through 3 years were evaluated. Kaplan-Meier estimates were used for late outcomes. An independent clinical events committee reviewed all events. The CT (computed tomography) scans through 1 year were reviewed by an independent core laboratory. RESULTS: The primary clinical success rate at 3 years was 84.0% (126/150). There were no aneurysm-related deaths, endograft migration, or aneurysm-related ruptures through 3 years. Stent fracture was detected in 2 subjects (1.3%) without clinical sequelae. Over 3 years, freedom from overall mortality was 89.4%, freedom from secondary interventions was 80%, and freedom from aneurysm sac enlargement was 96.5%. The 3-year freedom from type IA and IB endoleaks was 93.3% and 98.6%, respectively. CONCLUSIONS: In a multicenter real-world study setting, the use of a low-profile INCRAFT device for AAA is associated with sustained clinical success and low rates of reinterventions through 3 years.Clinical ImpactLow-profile endografts have broadened the spectrum of patients with anatomic suitability for endovascular repair of abdominal aortic aneurysms (AAA). However, questions remain regarding the durability of the repair. The INSIGHT study evaluated the use of the INCRAFT System in routine real-world clinical practice, including patients with complex anatomies. The treatment was safe and effective. The results showed sustained clinical success over 3 years, with no aneurysm-related deaths or ruptures, and a high rate of intervention-free survival at 3 years. Despite the low-profile design of the endograft, the midterm results demonstrate the durability of AAA repair using the INCRAFT System. CLINICALTRIALS: gov Identifier: NCT02477111.
引用
- Torsello G, Bertoglio L, Kellersmann R, et al. Three-Year Safety and Efficacy of the INCRAFT Endograft for Treatment of Abdominal Aortic Aneurysms: Results of the INSIGHT Study. J Endovasc Ther. 2023. PMID: 38031973. doi:10.1177/15266028231214162
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。